Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

Saliva molecular testing showed strong accuracy for pulmonary tuberculosis. Read more about this nonsputum diagnostic approach.

Shares of BioAffinity Technologies (BIAF) popped around 20% in pre-market trading on Tuesday, after the biotech company shared a positive update from a new case study evaluating its non-invasive ...

Substances capable of mutating human genetic material—altering and permanently damaging it—are present in many everyday products. Researchers at Justus Liebig University Giessen (JLU) have, for the ...

In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and ...

Alzheimer's disease affects millions of people worldwide, yet the illness is hardest to catch at the very beginning, when new ...

SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in ...

The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...

Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and middle-income countries, especially the African and Western Pacific regions.

Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung testNumber of CyPath® Lung tests performed in 2025 increased ...

In this large international cohort of immunocompromised patients with ARF, we identified key risk and protective factors for mortality and intubation. These findings could improve outcomes by ...